Cancer originating in melanocytes
After a whirlwind of unfortunate events collided with Carrie Brophy, she found herself in a new world and the feeling of having little control over what her life was. Living in constant anxiety about what tomorrow would bring.Carrie, a mom of six, a wife, a pediatric nurse and most recently a melanoma survivor. In 2020 she was in an unfamiliar place, thrust to look inside herself and face her new reality. This is a must listen episode if you are trying to figure out this new world of cancer, to keep your head above water and deal with the fear and anxiety that comes with all of it.She talks about being in the “eye of the storm”…which is a perfect metaphor for when things are momentarily calm but there is a lot going on that needs to be dealt with. She bravely shares with us such an important message about her internal struggles and navigating her melanoma journey. For information and support through a Melanoma Diagnosis visit:AIM at Melanoma How do you sail through life? Join me on this endeavor! I would love to grow this amazing support community.If you have any thoughts on today's episode, or topics you'd like me to further touch on, reach me through my WEBSITE. Check it out here- SailingThroughLifePodcast.comStay Anchored ⚓Music Credit: Alex_MakeMusic ** Sailing Through Life Podcast is intended to educate, inspire and support you on your personal journey and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. All content is for general informational purposes only. If you are suffering from any psychological or medical conditions, please seek help from a qualified health professional.
2022 Stanley Cup champion Josh Manson is today's guest on the podcast. Josh is a defenseman for the Colorado Avalanche of the National Hockey League. Originally drafted by the Anaheim Ducks (2011), Josh made his NHL debut with the Ducks in 2014. Earlier this year, Josh was traded to the Avalanche and was a key contributor to their championship run in Denver. In this interview, Josh reveals the physical and mental challenges of the playoff run and winning the ultimate trophy in sports (including his day with Lord Stanley's Cup in Saskatchewan). He details the deal he made with God when his mom was diagnosed with stage 4 cancer and given only three months to live. Josh discloses the three books that have significantly impacted his faith and the spiritual disciplines that helped him this past season. You will be encouraged as he shares about his faith (and role of hockey chapel), family (his wife and growing family) and storied career. Subscribe to the Post Game with Paul Golden podcast wherever you listen to podcasts.www.PaulGolden.orgColorado Avalanche defenseman Josh Manson shares the story of his BEST DAY EVER - YouTube
Guest: Benjamin Izar, MD Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
"What type of bagels do you serve in a post-divorce party?" You'll have to listen to find out. This is the story of two brothers, twenty months apart, who lost their mother at a young age and were raised by a devoted father. Both, (shout out to Dad) are united by their desire for public service and giving back. One brother, Sam, loves to cook and gets to work at a Michelin-rated restaurant, only to realize that a neverending corporate-style rat race to an imaginary top isn't aligned with his values or desires. Hal, Sam's younger brother, wanted to change the world (politics) goes to college as a political science/economics major but spends a year with Teach for America. He becomes the accidental marketer but learns every aspect of growth marketing on his own. He is now the owner of a Webflow agency, the next generation of WordPress. Hal is betting his life and career on Webflow technology's promise of a visual interface that offers control and power to web development. Sam finds himself connected, at a deep emotional level, to his Jewish roots; "I grew up eating Jewish food and decided to make bread and bagels (that were really bad). I wanted to sell them and give the money back. We donated the money to Melanoma research.""Maybe baking and Jewish food will be something I can share with people." Sam joins a new restaurant in Chicago and gets laid off when Covid hits. He spends his time baking bread for laid-off people who didn't have enough to put food on the table. From baking bagels in his apartment, Sam realizes this is the time to rely on himself and starts Zeitlin Delicatessen, which isn't a brick-and-mortar but is based entirely on delivering food. As his brother Hal says, "Sam has the longest lines in the farmers' market...I feel bad for the other vendor." Sam goes on to figure out entrepreneurship on his own. Zeitlin is a testament to the love of helping others, feeding others, and supporting others. Best advice Hal ever got? "Meditate every day." You won't be able to resist the urge to find these guys and just hug them. They are genuinely hardworking, good people who may not make the cover of Forbes but will impact lives and businesses in a more personal way than what many strive for as validation for success.
El Dr. Jerónimo Rodríguez Cid, oncólogo médico adscrito al Instituto Nacional de Enfermedades Respiratorias en la Ciudad de México, México, junto con la Dra. Florencia Cuadros, oncóloga clínica del Hospital Eva Perón en Rosario, Argentina, nos comentan algunos de los estudios más destacados sobre el tratamiento del melanoma presentados durante el Congreso Anual de ESMO 2022 en París, Francia. Enfermedad temprana SWOG S1801: Estudio fase II, que aleatorizó 1:1 a 313 pacientes con melanomas cutáneos, acrales y mucosos en estadio IIIB-IV (confirmados histológicamente, medibles, clínicamente detectables y resecables) sin metástasis cerebrales, para recibir pembrolizumab como terapia adyuvante (cirugía seguida de 18 dosis del anti-PD-1) o neoadyuvante (3 dosis preoperatorias seguida de cirugía y luego 15 dosis del anti-PD-1). Se permitió la radioterapia después de la cirugía. El objetivo primario fue la supervivencia libre de eventos. IMMUNED: Resultados informados de supervivencia global (SG) del estudio fase II, multicéntrico, aleatorizado 1:1:1, doble ciego, que evalúa el tratamiento de nivolumab adyuvante solo o en combinación con ipilimumab vs. placebo en pacientes ≥18 años con melanoma primario desconocido o cutáneo en estadio IV sin evidencia de enfermedad (los pacientes fueron estratificados por sitio del estudio, sitio de metástasis y estado de PD-L1). El objetivo primario fue supervivencia libre de recaídas en la población con intensión de tratar, el tiempo hasta la progresión, la SG y, como objetivo secundario, la seguridad. Enfermedad avanzada SECOMBIT: Resultados actualizados de SG y una evaluación preliminar de biomarcadores del estudio secuencial, fase II, que aleatorizó a 251 pacientes con melanoma metastásico BRAF V600 no tratado, a tres brazos paralelos: encorafenib + binimetinib como terapia dirigida (brazo A), ipilimumab + nivolumab como inmunoterapia (brazo B) y la estrategia de "sándwich" con la terapia dirigida primero, cambiando a la inmunoterapia después de 8 semanas y volviendo a la terapia dirigida después de la progresión (brazo C). La SG fue el objetivo primario y los secundarios incluyeron la supervivencia libre de progresión total, la tasa de supervivencia a 4 años y una evaluación preliminar de biomarcadores. PIVOT IO 001: Datos de eficacia y seguridad del estudio fase III, aleatorizado 1:1 y abierto que evaluó bempegaldesleukina + nivolumab vs. nivolumab en 783 pacientes con melanoma no tratado previamente, no resecable o metastásico. Los objetivos primarios fueron la tasa de respuesta objetiva, la supervivencia libre de progresión (SLP), ambos por revisión central independiente ciega según RECIST v1.1, y la SG. Abstract LBA40: Estudio fase II, abierto, que aleatorizó a pacientes con melanoma irresecable/metastásico, con mutación BRAF V600 o NRAS, previamente tratado, a recibir múltiples combinaciones del fármaco naporafenib (LXH254). Se exploró la combinación con LTT462 (inhibidor de ERK1/2), con trametinib (inhibidor de MEK1/2) o con ribociclib (inhibidor de CDK4/6). El objetivo primario fue evaluar la eficacia de las combinaciones de naporafenib en función de las tasas de respuesta globales y los objetivos secundarios fueron la seguridad y la tolerabilidad. Abstract LBA3: Estudio fase III, aleatorizado 1:1, multicéntrico y abierto, que evaluó el tratamiento con infiltrado de linfocitos tumorales (TIL, por sus siglas en inglés) vs. ipilimumab, en 168 pacientes con melanoma irresecable en estadio IIIC-IV (86% eran refractarios al tratamiento anti-PD-1). El objetivo primario fue la SLP según RECIST 1.1 y los objetivos secundarios fueron la tasa de respuesta general y completa, la SG y la seguridad. Fecha de grabación: 22 de
I loved this conversation with David Stanley because he breaks love down to the very simple idea of being good and decent. When you look at love in those simple forms you can apply it to business, friendships, life, science, and everything else. This is what David does and that makes for a great conversation. Bio David L. Stanley, B.Sc, M.A., is a teacher, poet and author, voice-over actor, and speaker. His work has appeared in national magazines on topics from professional bicycle racing to men, depression, and suicide. His first book, Melanoma, It Started with a Freckle was hailed by Prof. Tom Foster of How to Read Novels Like a Professor as “harrowing, insightful, technical, and hilarious.” Stanley's second book, co-authored with Willie Artis is From Jim Crow to CEO, the Willie Artis Story, available via AUX Media. His latest book is Rants & Mutters, an essay collection. In addition, you can read his poetry on his Medium page. Much of his prose is found on his personal blog, Rants & Mutters, and his Vocal.Media page. David Stanley has read his sonnets to audiences at the Dad 2.0 Summit; North America's largest gathering of dads and brands. His poetry has been featured in blogs and literary magazines. He is the narrator of 40 audiobooks on subjects ranging from Alzheimer's, bicycle racing, the NBA, to mountaineering. Stanley travels to speak on melanoma awareness, fatherhood and life, and The Art of the Pitch. Social Media Instagram: https://www.instagram.com/dstan_58/Facebook: https://www.facebook.com/MelanomaBook/Twitter: https://twitter.com/DStan58Linkedin: https://www.linkedin.com/in/david-stanley-26809b3b/Youtube: https://www.youtube.com/channel/UC0QzyesToNnTvJ_JhcBE5NQPodcast: https://getpodcast.com/dk/podcast/cycling-legends-history-podcast-free-version-no-premium-access/the-feed-zone-episode-2_5b5bbdccd6TikTok: https://www.tiktok.com/@dstan58
Dr Davies hosts Dr Mitchell on Podcast #4 to discuss adjuvant and neoadjuvant treatment approaches for patients with melanoma. Credit available for this activity expires: 9/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/980272?src=mkm_podcast_addon_980272
Sabe-se que o Pembrolizumabe prolonga a tanto a SG quanto a SLPem pacientes com melanoma avançado. Neste episódio, os Drs. Allan Pereira e Rodrigo Munhoz (Sírio Libanês SP) discutiram o KEYNOTE-716 que avaliou o uso do pembrolizumabe como terapia adjuvante em pacientes com melanoma de estágio II de alto risco completamente ressecado. Estudo importante, fase 3, randomizado que envolveu 160 Centros em várias partes do mundo, incluindo o Brasil. Nele foram recrutados pacientes com melanoma completamente ressecado estágios IIB ou IIC (TNM T3b ou T4 com biópsia de linfonodo sentinela negativa). Entre 2018 e 2020, quase 1.200 pacientes foram recrutados. Com um tempo de follow-up de cerca de 14 meses, 54 (11%) de 487 pacientes no grupo pembrolizumab e 82 (17%) de 489 no grupo placebo recaíram ou foram a óbito: HR 0,65 (IC 0·46–0·92), (p=0·0066). Uma segunda análise com tempo médio de follow-up de 21 meses, 72 (15%) pacientes no grupo pembrolizumab e 115 (24%) no grupo placebo recaíram ou foram a óbito: HR 0,61 (IC 0.45-0.82). Sejam bem-vindos a mais um episódio do Clinical Papers Podcast! Para saber mais sobre o paper, acesse: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00562-1/fulltext
Dr Davies hosts Dr Tawbi in a podcast focused on treatments for patients with melanoma with brain metastases. Credit available for this activity expires: [09/14/23] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/980050?src=mkm_podcast_series_980050
Melanoma is the most serious and deadliest type of skin cancer. Rates of melanoma have been rising for the past three decades, with this increase being largely blamed on exposure to ultraviolet light from the sun. However, is that really the case? According to research published in the British Journal of Dermatology, the sun is very likely nothing more than a scapegoat in regard to melanoma. Instead, these researchers concluded that the sharp increase in the number of cases may actually be due to “an artifact caused by diagnostic drift”—meaning that the rise in melanoma cases is significantly overstated, due to drifting in how doctors actually diagnose melanoma. ⭕️Watch in-depth videos based on Truth & Tradition at Epoch TV
AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas Equels joined Proactive's Stephen Gunnion after the company announced the start of an NCI-funded Phase 2 study of its product candidate Ampligen in melanoma. Equels gave an overview of Ampligen and explained the process for the Phase 2 study and the steps AIM will take if it is successful. He also provided an overview of the AIM's other programs with Ampligen. #ProactiveInvestors #AIMImmunoTech #Ampligen #NYSE
Melanoma is the most serious and deadliest type of skin cancer. Rates of melanoma have been rising for the past three decades, with this increase being largely blamed on exposure to ultraviolet light from the sun. However, is that really the case? According to research published in the British Journal of Dermatology, the sun is very likely nothing more than a scapegoat in regard to melanoma. Instead, these researchers concluded that the sharp increase in the number of cases may actually be due to “an artifact caused by diagnostic drift”—meaning that the rise in melanoma cases is significantly overstated, due to drifting in how doctors actually diagnose melanoma. ⭕️ Sign up for our NEWSLETTER and stay in touch
This week Bobbi Conner talks with Dr. Andrea Abbott about skin cancer screening and finding cancer in its earlier stages when it's easier to treat. Dr. Abbott is a surgical oncologist and Medical Director of the Melanoma and Advanced Skin Cancer Program at Hollings Cancer Center at MUSC.
James Templeton is a Stage 3 Melanoma cancer survivor. After conventional treatments failed, James immersed himself in the world of alternative therapies – discovering modalities like a macrobiotic diet and intravenous vitamin C therapy. His successful experience in healing his cancer through natural therapies led to his founding of Uni Key Health Systems and the Templeton Wellness Foundation, in addition to authoring a book, titled I Used to Have Cancer. James shares his healing story and encourages others to navigate their own path back to health.
What is the value of completion lymph node dissection for patients with melanoma with sentinel-node metastases? The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) confirmed that SLNB is an important part in the treatment of patients with melanoma, but what needed to be done beyond that in managing the axilla? Learning Objectives: In this episode, we review perioperative chemotherapy regimens for locally advanced, resectable Gastric cancer, standard of care, and the future role for immunotherapy. Hosts: Adam Yopp, MD, FACS (@AdamYopp) is an Associate Professor of Surgery at the UT Southwestern Medical Center and is Chief of the Division of Surgical Oncology. He also serves as Surgical Director of the Liver Tumor Program. Caitlin Hester, MD (@CaitlinAHester) is a new Assistant Professor of Surgery at the University of Miami Gilbert Murimwa, MD (@GilbertZMurimwa) is a PGY-4 General Surgery Resident at the UT Southwestern Medical Center and a research fellow in the Hamon Center for Therapeutic Oncology Research. Papers Referenced in this Episode: Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma Morton et al. https://www.nejm.org/doi/full/10.1056/nejmoa1310460 Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma Faries et al. https://www.nejm.org/doi/full/10.1056/nejmoa1613210 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our Journal Review Series here: https://behindtheknife.org/podcast-series/journal-review/
I didn't ask for cancer, but it sure found me! It found me in an aggressive way 5 years ago. I watched my so-called normal life implode. This wasn't my first big fight, but it was one of those final straw moments. It was an abrupt stop in life as I knew it. Having the feeling that something is really wrong and then hearing “you have cancer” wreaks havoc in your world. It was like a black hole opened up and sucked me in. I'm not a dramatic person, but I can tell you it surpassed anything I had experienced before.I started this show almost 2 years ago. It was 3 years after my first cancer diagnosis, after multiple surgeries, 2 years of cancer treatments and recently getting the all clear on a scan. The world was adjusting to this new realm of living in a world struggling to understand a pandemic.I had to figure life out in a whole new way to live, to think and be. To find peace…Listen to hear more about my story.How do you sail through life? Join me on this endeavor! I would love to grow this amazing support community.If you have any thoughts on today's episode, or topics you'd like me to further touch on, reach me through my WEBSITE. Check it out here- SailingThroughLifePodcast.comStay Anchored ⚓Music Credit: Alex_MakeMusic ** Sailing Through Life Podcast is intended to educate, inspire and support you on your personal journey and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. All content is for general informational purposes only. If you are suffering from any psychological or medical conditions, please seek help from a qualified health professional.
Who needs a hole in your head when you have a melanoma in your neck? In this Boles.tv live stream highlight, David Boles shares his melanoma experience and how new medical interventions are saving more lives than ever from skin cancer!
Brown University is saying in a recent study that fish is what's causing melanoma. Dr. Martin says the study sounds fishy and explains why he doesn't agree with their deduction. There are 3 basic types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Melanoma is the most deadly form of skin cancer, and Dr. Martin agrees that melanoma rates have really skyrocketed. But, not because of mercury in fish. It's because of high fructose corn syrup! Join Dr. Martin in today's episode as he teaches on the real cause of melanoma and explains why cases are now so prevalent!
Our latest podcast features Robert Dellavalle, Professor of Dermatology, Colorado School of Medicine, Professor of Public Health at the Colorado School of Public Health, and physician at the University of Colorado Hospital, all based in Aurora, Colorado, USA. Dellavalle and our host, Jonathan Sackier, discuss all things dermatology, from different skin conditions to community outreach programmes and the rise of telemedicine.
This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. --- Dr. Canter is a Surgical Oncologist with clinical expertise in the multidisciplinary management of sarcomas. He also runs a translational research laboratory which focuses on the therapeutic and mechanistic effects of combining natural killer (NK) cell immunotherapy with other treatment modalities to overcome NK dysfunction in the tumor microenvironment of solid tumors, including sarcomas in both humans and dogs. He serves as the co-leader of UC Davis Comprehensive Cancer Center's Comparative Oncology Program, and his laboratory is one of a select group of labs internationally which is studying canine NK cells, including first-in-dog studies of canine immunotherapy and adoptive transfer of NK cells in dogs with osteosarcoma. Dr. Rebhun is a an Associate Professor in the Department of Surgical and Radiological Sciences at the Center for Companion Animal Health at the UC Davis School of Veterinary Medicine. His research focus is in the field of comparative and translational oncology, with specific interests in metastasis and novel therapeutics. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.
Also, "wearable tech" is "reimagining" the course of annual physical examinations that Medicare encourages participants to take. Maybe the results will be that mush more valuable! Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Inspired by: "MEDICARE FOR THE LAZY MAN 2022; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com
Julie Randall didn't want to turn 50. Then, an unexpected diagnosis turned her world upside-down. Julie tells Cam and Ali her amazing story of love and determination that changed her relationship with life. LINKS Buy Julie's book Patient 71 — http://bit.ly/Patient71Booktopia Follow Julie on Facebook @julierandallpatient71 Follow Julie on Instagram @patient71_ Find out more about Julie on her website — https://julierandall.com.au/ Watch Julie's 60 Minutes story — https://www.youtube.com/watch?v=g3R4KNCj-6s&ab_channel=60MinutesAustralia Follow Cam on Instagram @camerondaddo. Follow Ali on Instagram @alidaddo. Follow Nova Podcasts @novapodcastsofficial. Got a question for Cam & Ali? You can email them at firstname.lastname@example.org. CREDITS Hosts: Cameron Daddo and Alison Brahe-Daddo. Guest: Julie Randall. Managing Producer: Elle Beattie. Producer and Editor: Amy Kimball. Find more great podcasts like this at novapodcasts.com.au. Nova Entertainment acknowledges the traditional custodians of the land on which we recorded this podcast, the Gadigal People of the Eora Nation. We pay our respect to Elders past and present. See omnystudio.com/listener for privacy information.
Kaitlin Yakura, wife of Dean Yakura, who finished last season in the ECHL for the Greenville Swamp Rabbits, joins me on Breaking the Ice and shares with me her journey of finding out she has Stage 3 Melanoma at age 25. In this Episode we discuss: Getting Diagnosed with cancer and what this emotional process looked like for her What she had going on in her life and how it had to be put on hold What chemotherapy was like and how cancer affected her confidence and self-esteem How growing old is a privilege and the unknowns that cancer can cause in the big picture of life The ways in which she felt the most supported by friends and family How therapy was a huge part of her healing process The importance of being an advocate for yourself and your health Follow me on Instagram Follow Kaitlin on Instagram Resources for Cancer + Melanoma: AIM Melanoma Foundation: CancerCare American Cancer Society
Have you realized your purpose in life? Investing and achieving financial freedom are all life goals, but they can still be meaningless without other purposes. Kevin Roth is a Life Coach who has been successful in his career as an artist. Despite his success, he realized that life is short, and when he was diagnosed with Melanoma, that changed his life. Listen as he shares his discoveries on how to survive and be financially successful and become truly happy and thrive. Come and join our mastermind group! Head on to https://simplepassivecashflow.com/club
In this episode of SurgOnc Today®, Tina Hieken, MD, Jeffrey Farma, MD, and Danielle Bello, MD, discuss the evolving role of surgery in the contemporary management of patients with Stage IV melanoma. The discussion includes the changing role of surgery for patients with metastatic melanoma in the current landscape of efficacious systemic immunotherapies and targeted therapies, and the role of surgical oncologists in clinical trials testing new and expanded approaches such as adoptive T cell therapy for patients with advanced melanoma.
Today's guest has been a college basketball player, Customer Service Manager then after his daughter was born, he became a police officer with the Cincinnati Police Department, where I was a SWAT Hostage Negotiator. In early 2012 he was diagnosed with a rare form of Melanoma, which presented on the bottom of my foot. By the time the melanoma was detected, it had metastasized to a lymph node in my groin. After two surgeries to remove the tumours, he was put on a weekly injection of the drug, Interferon, to help keep the disease from coming back. He took those weekly injections for almost 5 years before the Interferon became so toxic to my body that I ended up in the Intensive Care Unit with a fever of 108 degrees. There were times he felt so poorly and was in so much agony that he prayed to die. Each day was a struggle to use his mind to override his body's apathy and distress. One thing he learnt during all his pain and suffering is that you have two choices. You can succumb to the debilitating discomfort and misery, or you can learn to embrace it and use it to make you a stronger and better human being and he chose the latter. I realize pain and discomfort can beat you to your knees and keep you there if you let it. But I also came to appreciate that I could use my hurting and anguish to make me stronger and more resolute. He has recently written a book, entitled Sustainable Excellence, Ten Principles to Leading Your Uncommon and Extraordinary Life, to help people find and live their uncommon and extraordinary life. His hope is that people who read the book will lead a life of significance, as well as a life of success. If there is one thing, he's learnt is that as long as you don't quit, you can never be defeated. Find Terry here www.motivationalcheck.com www.facebook.com/motivationalcheck www.instagram.com/sustainableexcellenceauthor
Whether swimming in the pool, a trip to the lake or a day at the beach, summertime often means sun exposure. And protection from the sun is the focus of Summer Sun Safety Month every August.Skin cancer is the abnormal growth of skin cells. While it most often develops on skin exposed to the sun, but it also can occur on areas of skin not ordinarily exposed to sunlight. Skin cancer is the most common form of cancer in the U.S."And the incidence of skin cancer is rising," says Dr. Dawn Davis, a Mayo Clinic dermatologist. “We all want to be on the Earth longer, and we appreciate time and aging. But the older we are, the higher our risk for skin cancer.” The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma. Early detection of skin cancer gives you the best chance for successful skin cancer treatment.While it is common to have freckles and moles develop over time, it is important to know your skin and recognize when changes occur."It's important to know what skin lesions you have," explains Dr. Davis. "Know what they look like, so that if they change, you can come to the dermatologist or health care provider for evaluation."Melanoma is the most serious and deadly form of skin cancer. Dr. Davis says the "melanoma alphabet" can help with early detection: Asymmetry Look for moles with irregular shape. Border Look for moles with irregular, notched or scalloped borders. Changes in color Look for growths with different or uneven colors. Diameter Look for new growth of more than one-quarter of an inch in diameter. Evolving Look for changes over time. While melanoma is more common with age, pediatric melanoma can occur.“Often, it's not on everyone's radar because we don't believe that children can have skin malignancy, but that is not true,” says Dr. Davis. “It's simply less common. When children get melanoma, they can present with the same signs and symptoms as adults. However, they can also have different symptoms. Pediatric melanoma tends to be skin-colored or amelanotic more commonly than dark or pigmented. So, if a child develops a skin-colored, pink or red bump, or something that used to be flat and then becomes raised, that would be of concern.” On the Mayo Clinic Q&A podcast, Dr. Davis discusses skin cancer detection and treatment. Dr. Davis also recommends steps to take to protect your skin including avoiding ultraviolet rays, and wearing sunscreen and protective clothing.
Melanoma is the deadliest form of skin cancer. Such dangers prompt many people to stay out of the sun. But could sun-avoiding behavior actually be to our own peril? A Swedish study shows a surprising relationship between sun-avoiding behavior and mortality. Internal medicine and sleep specialist Dr. Robert Seheult says diseases, like dementia and diabetes, have increased as people spend less time in the sun. Psychiatrist Dr. Jingduan Yang describes patients with depression who sleep on the ‘sunny side' of the bed leaving hospital earlier than those who don't. Traditional Chinese medicine focuses on the connection between the human body and nature. To Dr. Yang, the body's circadian rhythm is like an internal sun inside of us. Is it a coincidence that the vast majority of his patients with mental illness have correspondingly low levels of vitamin D? In this episode of #VitalSigns I seek out the benefits of sun exposure with the experts and probe the age-old question of how to get more sun safely. ⭕️Watch in-depth videos based on Truth & Tradition at Epoch TV
A Cure in Sight is joined by Dr. Tim Murray, an ocular oncologist with over 30 years in the field of treating primary tumors (eye tumors) of ocular melanoma to discuss: Small Choroidal Melanoma: Advances in Treatment with Laser. Timothy G. Murray, MD, MBA is currently the Founding Director/CEO of Ocular Oncology and Retina of Miami Florida. Dr. Murray's early academic career was focused on the development of an integrated Ocular Oncology service beginning at the Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center. In 2012, Dr. Murray founded the Ocular Oncology and Retina Center in Miami, Florida, and has had 10 years in private practice. Dr. Murray continues as Tenured Professor Emeritus in Ophthalmology and Radiation Oncology with the Bascom Palmer Eye Institute/Sylvester Comprehensive Cancer Center. Dr. Murray's focus on founding the private Ocular Oncology and Retina Center was related to his ongoing pursuit of excellence in clinical care particularly targeted on advanced imaging and treatment technologies. Dr. Murray's Ocular Oncology and Retina Center continues to provide International, National and Regional care for patients with life- and sight-threatening complex eye disease. His interview is chalk full of insights and updates in research in the field; referencing a few key studies presented at the 2022 ISOO conference this summer about the importance of early detection of eye melanomas, early and effective treatment of those melanomas, yielding better prognosis for patients, regardless of their genetic expression. He shares insights for what type of comprehensive eye exams are most important for detection, and concludes the conversation by breaking down the laser treatment therapy option for small melanomas. The pros and cons are explored, as well as the types of tumors best suited for this emerging eye treatment. LIST OF OCULAR ONCOLOGISTS DR. MURRAY WOULD REFER TO ASIDE FROM HIMSELF ANNOUNCEMENTS: Lookin' For a Cure Arizona 5K Walk for Ocular Melanoma COMING UP September 24, 8 AM Register here and be sure to bring friends and family to walk with us! (Virtual option coming soon) Eye Believe Survivorship Seminar in Nashville, Tennessee October 14-15. REGISTER HERE! (Welcome reception for in person attendees on October 13, 6:00 PM) (Virtual and in person options.) Lookin' For a Cure TEXAS 5K Walk for Ocular Melanoma NOVEMBER 5, 2022; 8 AM Register here and be sure to bring friends and family to walk with us! (Virtual option available) Lookin' For a Cure LA 5K Walk for Ocular Melanoma in memory of Laurie Walters NOVEMBER 12, 2022; Registration details coming soon! Email email@example.com for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via PAYPAL OR VENMO or reach out directly to firstname.lastname@example.org The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. This podcast was hosted by Danet Peterson and produced by Page Fronczek.
Surgical Innovations for Prostate Cancer Treatment with guest Dr. Isaac Kim August 14, 2022 Yale Cancer Center visit: http://www.yalecancercenter.org email: email@example.com call: 203-785-4095
Professor Piotr Rutkowski, of the Maria-Sklodowska-Curie National Research Institute, discusses how Poland is managing the influx of 5 million Ukrainian refugees since the war began and tells host Dr. John Sweetenham, of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, about the future health needs of Ukrainian refugees with cancer. TRANSCRIPT Dr. John Sweetenham: Hello. I'm Dr. John Sweetenham, the associate director for Clinical Affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast. My guest today is Professor Piotr Rutkowski, who leads the department of Soft Tissue and Bone Sarcoma and Melanoma at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Prof. Rutkowski is also the deputy director for the National Oncological Strategy and Clinical Trials, and serves as president of the Polish Oncological Society. Prof. Rutkowski spoke with us earlier this year as millions of people were fleeing the war in Ukraine, and he described the really remarkable response from both the Polish government and his institution to this crisis. He's back on the podcast today to tell us about cancer care for Ukrainian refugees 5 months into the conflict, and how health systems are coping with the influx of millions of refugees. He will also share his insights on the kind of support that will be needed long-term to care for these patients in the future. Our full disclosures are available in the show notes and disclosures relating to all guests on the podcast can be found on our transcripts at asco.org/podcasts. Professor Rutkowski, thank you for being on the podcast today. It's been about 4 months since we last spoke. How are you doing? Dr. Piotr Rutkowski: I'm very privileged that we can speak again. I'm talking probably on behalf of many Polish physicians and citizens involved with this dramatic situation of war in Ukraine and helping our patients and citizens from Ukraine. And I feel okay, but of course, the situation is still dramatic, and we don't know what will happen during the next months. What we can tell, first, is what has been changed for these last 4 months, it is the number. So as of now, almost 5 million people from Ukraine crossed the border between Ukraine and Poland. And we can estimate that about 3 million refugees stay temporary or maybe even permanently in our country. This is a completely new situation because it means that it's about 10% of our citizens now. And what didn't change but still the cancer care for Ukrainian patients is the extension of regular cancer care within our national oncology network and our national health fund with this Polish insurance system. And this is the same for patients in Poland. And so all refugees from Ukraine are entitled to receive the same care as citizens of Poland. Still, this extraordinary legislation, which was adopted by the Polish parliament, covers all the refugees of war, social security, and health insurance. And we have a better situation because all comprehensive cancer centers or major cancer centers organize the help with a hotline, not only on the level of the whole country but also on the center level in the Ukrainian language. And the majority of these centers have staff speaking the Ukrainian language. Moreover, what I can say as a president of Polish Oncological Society, recently, with the help of an educational grant, we bought electronic translators for major oncological cancer centers. So they can help in the situation, like in the emergency situation, when we have access to live talk. So they can be used in that situation. And in my opinion, it is very, very helpful. So this is the current situation. And of course, I will present further the structure of oncological patients from Ukraine in Poland now and what's been done. Dr. John Sweetenham: Thank you. It's really quite extraordinary to grasp that your patient population almost overnight increased by 10%. That's just quite extraordinary. What aspects of the cancer care would you say are working well at the moment and what are your greatest remaining challenges with this population as of now? Dr. Piotr Rutkowski: First, with this challenge for the pediatric cancer population, and about 1,000 children with cancer were evacuated from Ukraine. They were transported to the Ukrainian hub near Lviv in western Ukraine and thereafter to Polish hub. And with help of many nongovernmental organizations (NGOs) and many organizations, many hospitals from Europe but also U.S. and Canada, many institutions helped within this operation to transfer after triage the pediatric, so children with cancer, to Polish, German, and U.S. physicians. So more than 1,000 children were transferred to these different hospitals around the world—so Europe, the USA, and Canada. But of course, when we look at specific other issues with Ukraine refugees with cancer, first we have a very extraordinary situation and demography because the majority are women with children and only a very small percentage of males, mostly in older age. So when we looked at the cost of hospital admission of patients from Ukraine until May, the signs and symptoms were not in abnormal laboratory tests, or not otherwise classified. So generally, [these were] different conditions, mostly internal conditions. The second one was obstetric gynecology, so pregnancy, childbirth, etc. And the third in the rank were neoplastic diseases. I looked also carefully how it looks on the level of our institution because Maria Sklodowska-Curie National Research Institution is the largest oncological center in Poland. And we have the central part in Warsaw, but also we have 2 branches in Poland. So when we looked at the populations, all together, we had about 1,000 visits with new patients in our institutions. And number 1 was breast cancer. And second were gastrointestinal, and thereafter gynecology. And the fourth in the rank was melanoma and also soft tissue tumors or cancers probably related to the younger population. But melanoma was also relatively frequent. But number 1 was breast and reconstructive in all our branches. And of course, the distribution of patients is also different. In the whole of Poland, the largest numbers are in our region because probably because Warsaw is the largest city in Poland. So they have a lot of relatives or colleagues. So about 20% of patients from Ukraine are concentrated in our region, but more than 10% are also near Katowice or Gliwice. So it's Silesia and also near Krakow. So this central and southeastern part of Poland have the majority of Ukrainian patients now. However, of course, some of the patients were also transferred to other parts of Poland. But as I said, in some of the departments, more than 10% of patients are now from Ukraine, especially in breast cancer units and also gynecological units. When I look in the department which I'm chairing, department of soft tissue, bone sarcoma, and melanoma, we have mostly patients from Ukraine involved in the treatment of advanced melanoma, some with earlier stages, and some patients with sarcoma, especially if they were contacted by physicians from Ukraine specifically for this type of disease. But generally, the state of disease is a little bit more advanced. So, many of these patients are receiving neoadjuvant therapy in breast cancer or they are going directly to treatment of stage IV disease with modern drugs like immunotherapy or targeted therapy for melanoma. This is also the real situation. One of my points I want to mention is, if the access to the cancer care, regular cancer care probably is good for patients, but the problem with communication exists, and still I think that patients or citizens from Ukraine do not participate too much in prevention programs because the participation in mammography, cytology for cervical cancer and other screening programs are at very low levels. So, of course, it's a new situation for these people. But still, probably it will be one of the points for which we have to undertake some strategies. Because we do not know how to get information on if they will be staying longer in our country what we can anticipate for next months and even years. So this can be problematic because it means that we'll have more and more advanced stages of disease. Dr. John Sweetenham: It's very interesting, and of course not surprising, that you have this very skewed demographic of predominantly female patients. I wonder whether you have any insights into whether the—maybe resistance to screening is the wrong word—but the reluctance to be screened? Is that do you think, a reflection of screening services in Ukraine? Or do you think it relates more to the current stresses and priorities that these patients face? Dr. Piotr Rutkowski: I think whether it's first for our colleagues from Ukraine, it's a new situation, and they still are not in a normal life. So I agree that first, of course, the participation in the screening programs in Ukraine is on the lower level, but still, maybe the people do not consider staying here, staying at home, of course, and staying in their own country. So they are a little bit in between of normal life and living as refugees only. So they did not start all normal activities. And of course, the information about the screening programs, about the normally functioning health care, it's also probably a little bit more difficult for them because they may not understand all the details of our health care. So I think that it is one of the points which we have to think about for new strategical enterprises in the coming months. So as I mentioned, for normal access to health care, I do not foresee now that it's problematic. Of course, it can be problematic if we'll have a shortage of our people. But still, we can manage this on a regular level. But as I mentioned, when I talked to our colleagues from the department of prevention, the percentage of the people who are coming for screening programs is very low as compared to the total number of refugees. Dr. John Sweetenham: You mentioned that the future for many of the Ukrainian refugees is uncertain at the moment. Now that the heaviest fighting appears to be concentrated on the east of the country, are you seeing any signs that Ukrainian patients will be able to go home for their treatments at any point in the near future? Dr. Piotr Rutkowski: Yes, I think so. Some of the refugees even started to come back home to Western Ukraine, especially when they felt that it was a little bit safer. But as we know, still the situation on the front and the plans of the Russian invaders are not predictable. So we cannot say how even we can behave in this situation. So, for example, in my hospital, we have psychologists from Ukraine who first escaped from Donbas to Kharkiv. And when Kharkiv started to be shelled by bombs, they escaped to Poland. So it's sometimes really dramatic fates for these people. So, of course, the movements between the border are relatively high because some of the people are trying to come back because they feel more comfortable in their homeland, in the country where they can all speak one language, but others they feel they've started to adapt to in living in Poland and we have more and more patients who are accompanied by people speaking Polish. So they started to try to live more normally in our country. I also noticed that we have some patients from Ukraine in the clinical trials. Of course, we also adapted the informed consent and some information sheets into the Ukrainian language. So Ukrainian patients interested in taking part in clinical trials are also included based on normal inclusion criteria. This is also important that we can propose this to patients from Ukraine because if they want to stay longer so they can get extra treatment within the frame of clinical trials. What is also interesting with our National Science Center is that it started to support researchers who are fleeing from war. And they prepared the special funding scheme for researchers from Ukraine to encourage the grant winners to employ researchers from Ukraine on ongoing projects. So there are many specific actions to adapt the citizens of Ukraine in Poland, and of course allow them to undertake normal work. We also allowed for specific temporary work in health care for physicians and nurses. And as it was announced recently by the Polish Minister of Health, more than 2,000 physicians from Ukraine decided to work in the Polish health system. So this is what we can do now. And probably we can do follow-up in half a year again. We'll see what will happen. Dr. John Sweetenham: I thank your responsiveness and that view of government. So this situation has been really remarkable and also remarkably quick. And as you've already pointed out, these patients are going to have needs for many months and many years to come. And you've touched on some of those, specifically the needs around cancer screening. Do you have any other insights into what you think the most pressing future needs for these refugees will be? And then what support your health system, which is presumably already overstretched, what additional support will it need to cope with the ongoing demands and needs of this population? Dr. Piotr Rutkowski: We really appreciate the help from the international community with material for our Ukrainian patients. Probably the next step will be a specific maybe European Union (EU) fund for a health care system which is affected now by numbers of patients from Ukraine, because, of course, we are doing this with our internal Polish funds. But I don't know how it would affect the next year with regular health service in Poland. So this is one of the points. The second point, of course, which we are always afraid of is the situation with the staff shortage for regular health care because Poland, generally in our part of Europe, we can see the shortage of nurses and educated oncological physicians. This is what we included in our national oncological strategy. However, we didn't anticipate it would have such an extraordinary situation which we have to face now. So these points can be one of the problems which can be raised next month. Dr. John Sweetenham: And so you you've indicated the potential support from the EU and other international agencies. I wonder if we could take that question a little bit further to the international oncology community, including organizations like ASCO, the European Cancer Organization (ECO), the American Cancer Society, and others, who've been collaborating to support Ukrainian patients and the oncology community in Poland and in the region. How do you think the international oncology community can continue to respond and help in the coming months and years? Dr. Piotr Rutkowski: It seems that it's a very continuous effort. So we have regular meetings between the national representatives, ECO, as you mentioned, ASCO, and also some NGOs to discuss the hottest problems with the situation in Europe and also how we can find solutions. Colleagues from Ukraine are also asking us about these specific issues like access to radiation therapy and the possibility to transfer the patients because the equipment is not working perfectly in the whole of Ukraine. This effort is very, very important. I feel that it will be a very excellent platform for next month, maybe for next year. I think that it's extraordinary because it was organized very fast, and it was not temporary, but it seems that it will be continuous for a long time. As I mentioned in this platform, we can exchange some materials, and some information very quickly and in an efficient way. I would like to thank you, ASCO, and ECO for the organization of this platform. Dr. John Sweetenham: Well, Professor Rutkowski, I want to thank you again for taking the time to join us for a follow-up discussion regarding the situation in your country with respect to Ukraine, and express, once again, our respect and admiration for the way that you and your colleagues and your country have responded to the crisis. It's been a real pleasure having you on the podcast today. So thank you for joining. Dr. Piotr Rutkowski: Thank you very much. Goodbye. Dr. John Sweetenham: And thank you to our listeners for your time today. If you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate and review us wherever you get your podcasts. Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Piotr Rutkowski: Honoraria: Bristol-Myers Squibb, MSD, Novartis, Roche, Pfizer, Pierre Fabre, Sanofi, and Merck Consulting or Advisory Role: Novartis, Blueprint Medicines, Bristol-Myers Squibb, Pierre Fabre, MSD, Amgen Speakers' Bureau: Pfizer, Novartis, Pierre Fabre Research Funding (institution): Novartis, Roche, Bristol-Myers Squibb Travel, Accommodations, Expenses: Orphan Europe, Pierre Fabre Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Interview was done May 17, 2022! I love meeting new people willing to let me in and share their “lemon to lemonade” experience! This story is about Kevin and a sudden diagnosis of Melanoma changed his life. He had a choice to accept a death sentence or to live. He chose life. He found a simple and powerful method to change how he lived by using his music from his dulcimer. Kevin discovered how to become truly happy and thrive and he asks us to ponder: What moves and inspires you? What message do you get from this interview? Website: https://kevinroth.org ABOUT the LemonAid Stand: Heidi started hosting the LemonAid Stand live radio talk show, over 20 years ago, in 1999! It all came about when Heidi was dealing with thoughts of suicide, inadequacy, and dealing with infertility. She realized as she reached out to others and heard their stories, she would be uplifted and inspired no matter what she was going through. So this podcast has old "Original" shows from that time period. It also has "New" shows that are currently being recorded with new guests. And it has "Update" shows where Heidi reached out to original radio show guests to find out how the past 20 years have been! Heidi is a motivational speaker and would love to speak at your event about how to elevate your happiness! Theme song written and recorded by Heidi's baby brother Shane! Do you know a story that needs to be shared? Contact Heidi! Email: LemonAidStandRadioShow@gmail.com Website: https://www.heidislemonaidstand.com Facebook: https://www.facebook.com/HeidisLemonAidStand Mail: PO BOX 926, Orem, Utah 84059
Visionary, ambitious women sometimes struggle with the idea of rest. But what if rest is a strategy? What if we can rest in God's divine power, knowing that He has given us ‘all that is required for life and godliness? On this episode of B.A.D. Christian podcast, I share my Facebook live conversation with Brooke Thomas around 2 Peter 1:3, describing the richness of being in a relationship with God and experiencing His extravagant love. We explain how God is calling you to completion, challenging you to adopt the honor scale for growth in business, and partner with the Lord to live out your calling. Listen in for Brooke's advice to women on honor and how to rest in His divine power to get to the next level in YOUR life and business! Brooke Thomas is the CEO of Live Out Loud. Brooke is a powerhouse entrepreneur who has built an 8-figure empire empowering business women to write their own rules for success. Brooke has proven herself as an Elite Level Business Strategist leading multiple Masterminds and operating an exclusive membership-based coaching program. The Live Out Loud Masterminds operate strategically with systems that have proven to help thousands of women take their business to a level of success that they never knew was possible. Brooke hosts a successful weekly podcast, The Live Out Loud Show, giving women a free resource to create a major impact in their business, life and faith. Brooke is also recognized as a top network marketing leader, having risen to the top at two separate companies. Brooke has mastered the science of recruiting, sales growth, duplication, and advanced mindset training while building a community of proven leaders that love what they do. Brooke has a heart for the underserved and as a result, started a non-profit named Love Out Loud. Love Out Loud brings Faith-based business women together by offering them the opportunity to amplify their impact in the world by pooling their resources for the greater good. Brooke's journey began with her cancer diagnosis in 2004. She was diagnosed with stage 3 Melanoma diagnosis which was the catalyst to change her life and accelerate her pathway to success. Brooke is a highly sought after motivational and keynote speaker, author, and has been featured in numerous media outlets including Forbes, Huffington Post, and has appeared on multiple television networks. Brooke continues to be cancer free and is determined to live her life OUT LOUD with her family in Newport Beach, California and teach other women to do the same. Connect with Brooke Thomas Live Out Loud Podcast Brooke on Instagram Brooke on Facebook Resources 2 Peter 1:3 Isaiah 40:31 Matthew 5:4 The Parable of the Talents Still: 7 Ways to Find Calm in the Chaos by Jenny Donnelly Pastor Clyde Lewis
"Everything is figureoutable" - Marie ForleoEPISODE OVERVIEW: So what happens when a little girl from North Dakota loses her grandmother, father, and is raped, all in a short period of time? Then, what if the mother doesn't take action and the little girl gets raped again by the same evil people years later? These hard questions were the real facts of this week's guest life.In this episode you'll learn about dealing with grief. Whether it's the loss of a loved one, abandonment, the destruction of an emotional connection, rape, losing your purity, or so many other reasons we experience grief in our lives. Today's guest has had many of the grief sources listened, and not only went through the darkness, but emerged into the light. So get your pens and paper ready, make sure that you're open to listen, and be ready to share this special episode with your friends and family who are suffering. Ladies & Gentlemen, welcome to the Victoria Volk story!GUEST BIO: Victoria is a self-published author, Adv. Cert. Grief Recovery Specialist®, Creator & Podcast Host of Grieving Voices, Reiki Master, YouMap® Cert. Coach and End-of-Life Doula. She aims to use her strengths and skills through a variety of offerings to help those whose lives have been upended by grief and loss go from surviving to thriving. When she's not helping hurting hearts, you can find Victoria enjoying quiet living with her husband, 3 teens, and pooch in rural ND.EPISODE PROUDLY SPONSORED BY: Ascend 2 Glory: Sales & Marketing Video Guide SHOW NOTES, GUEST CONTACT INFO, SPECIAL OFFERS, & OTHER RESOURCES MENTIONED:Guest Contact Info:Website: https://www.theunleashedheart.comInstagram: https://www.instagram.com/theunleashedheart/Facebook: https://www.facebook.com/victoriatheunleashedheart/Grieving Voices Podcast: https://podcasts.apple.com/us/podcast/grieving-voices/id1518129441Guest Special Offer(s):"For FREE e-books about grief, head to Victoria's website for those resources here: https://www.theunleashedheart.com/resources/free-ebooks/Resources Mentioned: Grief Recovery Handbook: https://amzn.to/3yFXAyx HOW TO SUPPORT THE REMARKABLE PEOPLE PODCAST:Subscribe, Rate, & Review us on YouTube, Apple Podcasts, Spotify, or your favorite Podcast PlayerSharethe podcast or specific episodes with your family, friends, and co-workersSponsor an Episode or Donate what you can financially to help us continue to bring great content that inspires you and people like you around the world! HAVE A QUESTION?Click Here to Connect with David THE NOT-SO-FINE-PRINT DISCLAIMER: While we are very thankful for all of our guests, please understand that we do not necessarily hold, or endorse the same beliefs, views, and positions that they may have. We respectfully agree to disagree in some areas and thank God for the blessing and privilege of free will.Support the show
Although melanoma in goats is quite rare, it is devastating when it does happen because there is no cure. In this episode, we are talking to Julie Jarvis PA-C, a retired Dermatology Physician Assistant who practiced human medicine for 21 years. She has also been a goat farmer since 2004, and one of her goats was recently diagnosed with melanoma.In my post on squamous cell carcinoma, I talked about how easy it is to misdiagnose it, and the same is true of melanoma. Since Julie had 21 years experience in human dermatology, she knew something was seriously wrong when she saw what most people would have assumed was an injury or hoof rot.Julie goes into detail about what she saw and what she did, as well as the research she found on melanoma in goats.See full show notes here >> https://thriftyhomesteader.com/skin-cancer-in-goats-melanoma/ To see the most recent episodes, visit ForTheLoveOfGoats.comWant to support the content you love?Head over to -- https://thrifty-homesteader.ck.page/products/love-goats-tip-jar
After losing a loved one due to a delayed melanoma diagnosis, our next guest is on a mission to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. Dr. John Dobak, CEO of DermTech, joins us to discuss how he and his team are creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. Join us to discover why and how Dr. Dobak and the DermTech team are revolutionizing melanoma detection. Let's go! Episode Highlights: Dr. Dobak's experience and passion for building DermTech The impact of losing a loved one due to melanoma DermTech's mission to disrupt the status quo in medicine Feedback from service providers using DermTech's new technology About our Guest: As President and CEO of DermTech, Dr. John Dobak oversees DermTech's strategic direction, resources and execution. Additionally, in his role as President, Dr. Dobak collaborates with DermTech's Board of Directors to establish short- and long-term company goals. A testament to his experience throughout the industry, Dr. Dobak is also the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies and CryoGen/CryoCor. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including the University of California, San Diego Connect's Most Innovative New Product and the Massachusetts Institute of Technology's TR 100. Dr. Dobak received a bachelor's degree from the University of California, Los Angeles and a medical doctorate from the University of California, San Diego. Links Supporting This Episode: DermTech website: https://dermtech.com/ (CLICK HERE) Dr. John Dobak LinkedIn page: https://www.linkedin.com/in/john-dobak-m-d-13bb25a/ (CLICK HERE) DermTech Twitter page: https://twitter.com/DermTech (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest nomination form: https://docs.google.com/forms/d/e/1FAIpQLScqk_H_a79gCRsBLynkGp7JbdtFRWynTvPVV9ntOdEpExjQIQ/viewform (CLICK HERE)